Prognostic Significance of Sentinel Headache Preceding Aneurysmal Subarachnoid Hemorrhage.


Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
07 2020
Historique:
received: 13 02 2020
revised: 10 04 2020
accepted: 11 04 2020
pubmed: 28 4 2020
medline: 27 10 2020
entrez: 28 4 2020
Statut: ppublish

Résumé

Sentinel headache (SH) is often assumed to portend an increased risk of delayed cerebral ischemia (DCI) and aneurysm rebleeding. This study aimed to re-evaluate the associations between SH and aneurysm rebleeding, DCI, and outcome after SAH. We retrospectively analyzed 1102 patients with spontaneous SAH and available data regarding history of SH who were enrolled in the Columbia University SAH Outcomes Project between 1996 and 2009. Patients were asked whether they had experienced any episodes of acute, sudden-onset severe headache in the 2 weeks preceding the most recent bleeding event. DCI was defined as neurologic deterioration, infarction, or both due to vasospasm. Rebleeding was defined as the appearance of new hemorrhage on computed tomography. Outcome was assessed at 3 months by telephone interview using the modified Rankin Scale. SH was reported in 152 (14%) of 1102 patients. There were no significant differences between patients with and without SH with regard to admission Hunt-Hess grade or modified Fisher Scale. There was also no difference with regard to the frequency of aneurysm rebleeding (10% vs. 8%, P = 0.42), DCI (18% vs, 20%, P = 0.64), moderate-or-severe angiographic vasospasm on follow-up angiography (51% vs. 56%, P = 0.43), highest recorded mean middle cerebral artery flow velocity on transcranial Doppler (134 versus 128 cm/s, P = 0.30), or the distribution of modified Rankin Scale scores at 3 months. A history of sentinel headache before the clinical diagnosis of SAH does not imply an increased risk of DCI or further rebleeding, and carries no prognostic significance.

Sections du résumé

BACKGROUND
Sentinel headache (SH) is often assumed to portend an increased risk of delayed cerebral ischemia (DCI) and aneurysm rebleeding. This study aimed to re-evaluate the associations between SH and aneurysm rebleeding, DCI, and outcome after SAH.
METHODS
We retrospectively analyzed 1102 patients with spontaneous SAH and available data regarding history of SH who were enrolled in the Columbia University SAH Outcomes Project between 1996 and 2009. Patients were asked whether they had experienced any episodes of acute, sudden-onset severe headache in the 2 weeks preceding the most recent bleeding event. DCI was defined as neurologic deterioration, infarction, or both due to vasospasm. Rebleeding was defined as the appearance of new hemorrhage on computed tomography. Outcome was assessed at 3 months by telephone interview using the modified Rankin Scale.
RESULTS
SH was reported in 152 (14%) of 1102 patients. There were no significant differences between patients with and without SH with regard to admission Hunt-Hess grade or modified Fisher Scale. There was also no difference with regard to the frequency of aneurysm rebleeding (10% vs. 8%, P = 0.42), DCI (18% vs, 20%, P = 0.64), moderate-or-severe angiographic vasospasm on follow-up angiography (51% vs. 56%, P = 0.43), highest recorded mean middle cerebral artery flow velocity on transcranial Doppler (134 versus 128 cm/s, P = 0.30), or the distribution of modified Rankin Scale scores at 3 months.
CONCLUSIONS
A history of sentinel headache before the clinical diagnosis of SAH does not imply an increased risk of DCI or further rebleeding, and carries no prognostic significance.

Identifiants

pubmed: 32339738
pii: S1878-8750(20)30804-4
doi: 10.1016/j.wneu.2020.04.097
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e672-e676

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Tanuwong Viarasilpa (T)

Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Priyanka Ghosh (P)

Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Suman Gidwani (S)

Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Hector Lantigua (H)

Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Gian Marco De Marchis (GM)

Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA; Department of Neurology & Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.

Nicha Panyavachiraporn (N)

Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

J Michael Schmidt (JM)

Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Kiwon Lee (K)

Department of Neurosurgery, Columbia University College of Physicians and Surgeons, New York, New York, USA; Department of Neurology, Rutgers-Robert Wood Johnson Medical School, The State University of New Jersey, New Brunswick, New Jersey, USA.

Neeraj Badjatia (N)

Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA; Department of Neurosurgery, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Sachin Agarwal (S)

Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Jan Claassen (J)

Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA; Department of Neurosurgery, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Stephan A Mayer (SA)

Departments of Neurology and Neurosurgery, New York Medical College, Westchester Medical Center Health Network, Valhalla, New York, USA. Electronic address: stephanamayer@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH